Understanding how pancreatic cancer responds to KRAS inhibitors
Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer
This study is looking at how certain gene changes in pancreatic cancer might affect how well new treatments work, with the hope of finding better, personalized therapies for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11023066 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer with a low survival rate. It aims to explore how mutations in the KRAS gene and other tumor suppressor genes affect the cancer's response to new KRAS inhibitors. By using advanced models, including human organoids and mouse models, the research will investigate the genetic and environmental factors that influence treatment outcomes. Patients may benefit from insights that could lead to more effective therapies tailored to their specific cancer profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with KRAS mutations.
Not a fit: Patients with non-pancreatic cancers or those without KRAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for pancreatic cancer patients, potentially increasing survival rates.
How similar studies have performed: Other research has shown promising results with KRAS inhibitors in similar contexts, indicating a potential for success in this area.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Aguirre, Andrew James — Dana-Farber Cancer Inst
- Study coordinator: Aguirre, Andrew James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.